J&J Says 250,000 Ebola Vaccine Doses to Be Ready by May

Johnson & Johnson plans to have 250,000 doses of experimental Ebola vaccine ready for clinical trials in May, potentially putting it ahead of GlaxoSmithKline Plc in the race to combat the virus that has killed thousands in West Africa.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.